Ernexa Therapeutics Inc. (ERNA) Dividend History

Company News

• Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

  Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line

  GlobeNewswire Inc.
• Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

  Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

  GlobeNewswire Inc.
• Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

  Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors

  GlobeNewswire Inc.
• Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

  CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that Eterna’s Board of Directors granted a non-qualified stock option to purchase 1,685,218 shares of Eterna’s common stock (the “Stock Option”) to its new President and Chief Executive Officer, Sanjeev Luther, effective January 1, 2024, the first date of his employment. The Stock Option was granted pursuant to the terms of Mr. Luther’s employment agreement and as a material inducement to his joining Eterna as President and Chief Executive Officer in accordance with Nasdaq Listing Rule 5635(c)(4).

  GlobeNewswire Inc.
• Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

  CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Officer.

  GlobeNewswire Inc.